^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    EGFR (Epidermal growth factor receptor)

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    21h
    Identification of epithelial, mesenchymal, and platelet-associated circulating tumour cells with translational implications in oral squamous cell carcinoma. (PubMed, Sci Rep)
    Taken together, our findings outline a practical workflow for identifying and quantifying different CTC-states in OSCC, with platelet-associated CTCs emerging as the predominant population detected. These findings support the importance of incorporating phenotypic heterogeneity and platelet-associated tumour cell interactions into future liquid biopsy-based translational pathology research and clinical biomarker development in OSCC.
    Journal • Circulating tumor cells
    |
    EGFR (Epidermal growth factor receptor) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • EPCAM (Epithelial cell adhesion molecule) • CDH2 (Cadherin 2) • ITGA2B (Integrin Subunit Alpha 2b)
    1d
    Study on the mechanism of action of Chaihu Guizhi Ganjiang Decoction for the treatment of slow transit constipation combined with depression based on network pharmacology and molecular docking. (PubMed, Medicine (Baltimore))
    CGGD primarily intervenes in STC combined with depression through pathways including the phosphatidylinositol 3-kinase-Akt signaling pathway, the mitogen-activated protein kinase signaling pathway, and the apoptosis pathway. Through an integrated network pharmacology approach, this study describes the synergistic effects of multiple ingredients, targets, and pathways of CGGD in the treatment of STC combined with depression.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
    1d
    Multiomic characterization of malignant pulmonary nodules and development of a methylation-based diagnostic Model. (PubMed, J Transl Med)
    This study delineates an epigenetic-transcriptional regulatory network that drives nodule malignancy. Our findings provide a robust theoretical foundation and a high-performance liquid biopsy tool for the precise, noninvasive diagnosis of pulmonary nodules.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD8 (cluster of differentiation 8) • GDF15 (Growth differentiation factor 15) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
    |
    EGFR mutation
    1d
    Consistency of c-Met protein overexpression over time in patients with non-squamous non-small cell lung cancer. (PubMed, Histopathology)
    These results indicate c-Met protein overexpression can be assessed before or after treatment since most patients maintain consistent c-Met status. As targeted therapies may elevate c-Met overexpression over time, retesting may be necessary in those with an oncogenic driver alteration initially diagnosed as c-Met negative.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET overexpression • MET expression
    1d
    Anti-osteoporotic potential of Lawsonia inermis leaf extract: integration of network pharmacology, molecular docking, and experimental validation in ovariectomized rats. (PubMed, Inflammopharmacology)
    LIEE exhibits significant anti-osteoporotic effects through a multi-targeted mechanism involving modulation of ER/OPG/RANKL signalling, suppression of inflammation and oxidative stress, and regulation of key molecular targets. These outcomes propose that LIEE could help as a capable phytotherapeutic candidate for the management of postmenopausal osteoporosis and warrant more clinical exploration.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • mTOR (Mechanistic target of rapamycin kinase) • IL6 (Interleukin 6) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • MMP9 (Matrix metallopeptidase 9) • IL1B (Interleukin 1, beta) • CAT (Catalase) • TNFRSF11B (Tumor necrosis factor receptor superfamily member 11B) • BGLAP (Bone Gamma-Carboxyglutamate Protein)
    |
    EGFR expression
    2d
    A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
    P1/2, N=67, Recruiting, D3 Bio (Wuxi) Co., Ltd | Active, not recruiting --> Recruiting | Trial completion date: Apr 2028 --> Aug 2028 | Trial primary completion date: Apr 2028 --> Aug 2028
    Enrollment open • Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    BRAF V600E • EGFR mutation • KRAS G12C • BRAF V600 • EGFR L858R • EGFR T790M • KRAS G12D • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • ROS1 fusion • EGFR G719X • MET mutation • EGFR S768I • RET rearrangement • KRAS G12 • KRAS G12S • KRAS Q61
    |
    D3S-002 • elisrasib (D3S-001)
    2d
    Bergenin Suppresses Glycolysis and Malignant Progression in Breast Cancer via the IGF1R-MAPK Signaling Pathway. (PubMed, Ann Clin Lab Sci)
    Ber suppresses glycolysis and malignant progression in BC through modulation of the IGF1R-MAPK signaling pathway.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • IGF1R (Insulin-like growth factor 1 receptor) • PHGDH (Phosphoglycerate Dehydrogenase) • KDM5B (Lysine Demethylase 5B) • LGALS9 (Galectin 9) • PKM (Pyruvate Kinase M1/2)
    2d
    Stage 4A Lung Adenocarcinoma with Rare EGFR Exon 21 L861Q and Exon 18 G719A Co-Mutations Showing Complete PET-CT Response to Osimertinib: A Case Report. (PubMed, Case Rep Oncol)
    This case demonstrates that osimertinib can achieve an early, deep, and sustainable response in patients with a rare G719A/L861Q co-mutation. Prospective evidence is necessary for rare EGFR subtypes.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR mutation • EGFR L861Q
    |
    Tagrisso (osimertinib)
    2d
    Precision Medicine in Treating Lung Cancer: A Narrative Review on Treatments Targeting Oncogenic Genetic Mutations. (PubMed, Cureus)
    However, the associated adverse effects of these agents, along with drug resistance, remain a challenge. In this review, we discuss targeted therapies for lung cancer, their efficacy, clinical trials, adverse effects, mechanisms of resistance, and future directions.
    Review • Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation
    2d
    Treatment decision-making for leptomeningeal metastasis after TKI resistance in EGFR-mutant lung cancer: a comprehensive review on staging, resistance patterns, and multimodal interventions. (PubMed, Front Neurol)
    To address this issue, we outline a clinical decision-making pathway aimed at helping physicians optimize and personalize treatment regimens. Looking ahead, improving our methods for identifying drug resistance mechanisms, optimizing central nervous system (CNS) drug delivery, and building stronger collaborative care models will be crucial for improving the prognosis of this vulnerable group.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    2d
    Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/DD) and Pure Urothelial Carcinoma Using a Large-Scale Japanese Genomic Panel Dataset. (PubMed, Int J Urol)
    Using a large-scale Japanese genomic panel dataset, we characterized the molecular alterations associated with S/DD. S/DD frequently exhibits low Nectin-4 expression and basal-like molecular features, which may have implications for treatment selection and inform future therapeutic strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • KDM6A (Lysine Demethylase 6A) • FGF4 (Fibroblast growth factor 4) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • GATA3 (GATA binding protein 3) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 expression • TP53 mutation • EGFR expression • ARID1A mutation • FGFR3 mutation • RB1 mutation
    2d
    Impact of time-of-day on immunochemotherapy efficacy in non-small cell lung cancer. (PubMed, Ann Med Surg (Lond))
    Future strategies should prioritize multicenter validation, integration of chronobiological profiling, and exploration of combination therapies. Cost-effectiveness analyses, awareness campaigns, and clinical drives to evaluate safety and adherence will be essential to establish trust and optimize outcomes.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    KRAS mutation • EGFR mutation • ALK mutation